Tech Company Financing Transactions
AbilityPharma Funding Round
AbilityPharma, based in Cerdanyola (Barcelona), scored $7.6 million from CDTI, CTI Life Sciences Fund and EIC Ventures.
Transaction Overview
Company Name
Announced On
3/11/2024
Transaction Type
Venture Equity
Amount
$7,600,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to finance its phase 2b clinical study of antitumor compound ABTL0812 in patients with pancreatic cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Avinguda Parc Tecnològic, 3, Centre d'Empreses de Noves Tecn
Cerdanyola (Barcelona), 08290
Spain
Cerdanyola (Barcelona), 08290
Spain
Phone
Undisclosed
Website
Email Address
Overview
AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds that produces autophagy-mediated cytotoxicity selectively in cancer cells. The first drug candidate, ABTL0812, is currently in phase 2b clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and squamous non-small cell lung cancer in Spain and France.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carles Domènech
VP - Administration
Vanessa Ruz
VP - Finance
Francesca Ribot
VP - Operations
Héctor Pérez-Montoyo
VP - Operations
Yolanda Soler
VP - Regulatory Affairs
Gemma Fierro
Browse more venture capital transactions:
Prev: 3/11/2024: NFTfi venture capital transaction
Next: 3/11/2024: DeBox venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs